The disappointing results of the large, randomized, controlled trials showing no benefit of vaccines in patients with advanced and metastatic melanoma call for a reassessment of the development of therapeutic vaccines and the importance of better immune monitoring methodology, such as adoptive T-cell therapy with lymphodepletion.

Additional Metadata
Keywords cancer staging, cancer vaccine, dose response, human, immunology, immunotherapy, interleukin 2, melanoma, metastasis, note, pathology, randomized controlled trial, skin tumor
Persistent URL,
Journal Nature Reviews Clinical Oncology
Eggermont, A.M.M. (2009). Immunotherapy: Vaccine trials in melanoma -- time for reflection. Nature Reviews Clinical Oncology, 6(5), 256–258. doi:10.1038/nrclinonc.2009.42